Catherine McCarty > Goodwin > Boston, United States > Lawyer Profile
Goodwin Offices
100 NORTHERN AVENUE
BOSTON MA 02210
MASSACHUSETTS
United States
- Firm Profile
- Go to...
Catherine McCarty
Position
Partner / Co-Chair Intellectual Property
Career
Cathy McCarty is a partner in Goodwin’s Technology and Life Sciences groups, and a co-chair of Goodwin’s Intellectual Property practice group. Cathy works with clients to protect their innovations and procure intellectual property through intellectual property strategies that are integrated with each client’s business goals. She works with public and private companies of all sizes and stages of development, including venture funded start-ups, venture capital partnerships, and entities that invest in, or evaluate, pharmaceutical and life science companies and technologies.
Cathy specializes in intellectual property relating to pharmaceuticals and general chemistry matters, including small molecule drugs, salt forms, solid forms, and chemical processes. She also has worked on various litigation matters involving pharmaceutical and chemical products.
Cathy approaches each client and each matter with the drive and focus required to master the project at hand. She works to integrate the intellectual property with the practical business issues faced by the client, including scientific, financial, regulatory, and competitive issues. Her client projects are varied and include designing and managing worldwide patent estates on drug candidates, evaluating competitive landscapes to determine patentability and freedom to operate, procuring IP strategy for early stage start-up companies, performing IP due diligence for investors, and advising on license agreements, collaborations, and regulatory issues.
Education
JD, 2002, Harvard Law School / MS, Chemistry, Yale University / BS, Chemistry, Indiana University (honors)
Lawyer Rankings
United States > Intellectual property > Patents: licensing
Standing out for its expertise in negotiating and executing complex transactions, Goodwin is a top destination for blue chip clients in the technology and life sciences industry. The firm is renowned for its vast experience enabling firms in the procurement and enforcement of patent rights and often receives high-profile licensing and collaboration mandates from both domestic and international clients. The practice is co-led by Boston’s Catherine McCarty who has specialist knowledge of pharmaceutical and chemical products, and James Riley, who leads the team from Silicon Valley with a unique understanding of technology acquisition and licensing. The team benefits from Steve Charkoudian’s extensive technology expertise and Kingsley Taft deep knowledge of the domestic biotechnology market, both of whom are based in Boston. Noelle Dubiansky, who is based in the firm’s Washington DC office, is another name to note.
United States > Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
(Firms to watch)Goodwin ‘s patent offering, led by Boston’s Catherine McCarty and James Riley in Silicon Valley has been bolstered by the February 2022 arrival of patent expert Scott Bluni and his team from Kacvinsky Daisak Bluni.
Lawyer Rankings
- Patents: licensing United States > Intellectual property
- Firms to watch United States > Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
Top Tier Firm Rankings
- Finance > Financial services regulation
- Industry focus > Cannabis
- Intellectual property > Patents: licensing
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Industry focus > Education
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Investment fund formation and management > Mutual/registered/exchange-traded funds
- Dispute resolution > Securities litigation: defense
- Finance > Capital markets: debt offerings
- International Trade > CFIUS
- M&A/corporate and commercial > Corporate governance
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Dispute resolution > E-discovery
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Intellectual property > Patents: litigation (full coverage)
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Real estate > Real estate
- M&A/corporate and commercial > Shareholder activism
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- Labor and employment > Employee benefits, executive compensation and retirement plans: design
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Healthcare > Service providers
- International Trade > Customs, export controls and economic sanctions
- Dispute resolution > Leading trial lawyers
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Commercial lending
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)